Medidata and Cognizant Form Strategic Alliance to Make Digital Transformation Accessible for the Life Sciences
February 11 2019 - 4:35PM
Business Wire
- Turnkey solutions will accelerate and
optimize operational aspects of a clinical trial by bringing
together industry-leading life science software with world-class
managed services
- Life science organizations of all sizes
and therapeutic areas can leverage enterprise-grade technology and
expertise to drive their digital transformation
Medidata (NASDAQ:MDSO) and Cognizant (NASDAQ:CTSH) have entered
into a strategic alliance to offer life science clients
comprehensive solutions that leverage the market’s leading cloud
platform with world-class business and technology services. This
provides pharmaceutical, biotech, medical device companies,
contract research organizations (CROs), sites and investigators
with digital capabilities to facilitate a fast start to clinical
trials, simplify operational complexities and drive digital
transformation.
As part of the multi-year agreement, Cognizant will develop and
deliver a comprehensive set of managed services and solutions
specific to Medidata’s platform. Cognizant’s expertise in business
process, technology and digital services (including biostats,
automation and help desks) will combine with solutions across the
Medidata platform, such as Randomization and Trial Supply
Management. This will create clinical capabilities as-a-service to
help address the increasing complexities and global scale of
clinical trials.
As an example of how Medidata is providing more choices for
customers, Medidata Site Payments will seamlessly connect with
Cognizant’s Shared Investigator Platform (SIP) -- the industry
standard platform designed to improve the experience of
investigators, sites and sponsors.
Clinical trials are becoming more complex to implement and
conduct due to big data, AI and the desire for more targeted
therapies. The professional services component of this alliance
provides life science companies with technology and expertise to
architect, implement and optimize studies.
“Most life science companies have stitched together multiple
legacy solutions and are in dire need for a clinical refresh. This
partnership allows us to offer and manage the most comprehensive
platform and suite of services for our clients so that they can
focus on the science rather than operational complexities,” said
Bhaskar Sambasivan, senior vice president and global head of life
sciences at Cognizant.
“This alliance exemplifies the power of Medidata’s technology
combined with the expertise of the broadest and most advanced
partner ecosystem, which we have built in life sciences,” said
Tarek Sherif, chairman and chief executive officer, Medidata. “We
are deepening our partnership with Cognizant to help customers
around the globe fully realize the value of digital
transformation.”
About Cognizant
Cognizant (Nasdaq-100: CTSH) is one of the world's leading
professional services companies, transforming clients' business,
operating and technology models for the digital era. Our unique
industry-based, consultative approach helps clients envision, build
and run more innovative and efficient businesses. Headquartered in
the U.S., Cognizant is ranked 195 on the Fortune 500 and is
consistently listed among the most admired companies in the world.
Learn how Cognizant helps clients lead with digital
at www.cognizant.com or follow us @Cognizant.
About Medidata
Medidata is leading the digital transformation of life sciences,
with the world's most used platform for clinical development,
commercial, and real-world data. Powered by artificial intelligence
and delivered by the #1 ranked industry experts, the Intelligent
Platform for Life Sciences helps pharmaceutical, biotech, medical
device companies, and academic researchers accelerate value,
minimize risk and optimize outcomes. Medidata serves more than
1,000 customers and partners worldwide and empowers more than
100,000 certified users every day to create hope for millions of
patients. Discover the future of life sciences:
www.medidata.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190211005729/en/
Medidata SolutionsInvestors:Betsy Frank, +1
917-522-4620bfrank@medidata.comorMedia:Erik Snider, +1
646-362-2997esnider@medidata.com
CognizantFor further information, contact:U.S.: Rick
Lacroix, +1-201-470-8961richard.lacroix@cognizant.comorJosh
Blumenthal, +1-267-244-2841Joshua.blumenthal@cognizant.com
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Apr 2023 to Apr 2024